RxDoctor Payments DataLook up a doctor →

James Sullivan, MD

Internal Medicine · Birmingham, ALNPI 1588613020

Payments from drug & device makers

$6,018,695in general payments, 2019–2025

Across 1,156 payments — averaging $5206.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2.8M
  • Eli Lilly$1.6M
  • Astrazeneca UK Limited$1.2M
  • Novartis$398K
  • AbbVie$17K
  • Indivior Inc.$13K
  • plus $22K from 54 others
$50,818in research payments, 2019–2025

Across 7 payments — averaging $7259.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$46K
  • Orexo US, Inc.$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca102$2,768,583
Eli Lilly9$1,606,813
Astrazeneca UK Limited9$1,192,301
Novartis28$398,098
AbbVie(2 entities)88$17,193
Indivior Inc.37$13,092
Novo Nordisk172$6,261
Amgen59$4,402
Lilly USA, LLC86$1,359
Pfizer66$985
GSK52$971
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC41$656
Johnson & Johnson42$637
Boehringer Ingelheim43$622
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$562
Nevro Corp.2$505
Otsuka America Pharmaceutical, Inc.21$467
Braeburn Inc.13$389
Takeda Pharmaceuticals U.S.A., Inc.15$276
Sanofi-aventis U.S. LLC14$276
Ironwood Pharmaceuticals, Inc18$270
Biohaven Pharmaceutical Holding Company Ltd.13$239
Teva Pharmaceuticals USA, Inc.18$226
Scilex Pharmaceuticals Inc.14$216
Ardelyx, Inc.10$216
Bausch Health US, LLC12$211
Esperion Therapeutics, Inc.9$160
Idorsia Pharmaceuticals US Inc3$154
Corcept Therapeutics9$149
Vanda Pharmaceuticals Inc.6$145
Pear Therapeutics (US), Inc.6$142
Sumitomo Pharma America, Inc.6$139
UCB, Inc.7$136
Lundbeck LLC5$132
Phathom Pharmaceuticals, Inc.6$122
Bayer6$115
Biohaven Pharmaceuticals, Inc.6$105
Amarin Pharma, Inc.7$103
Jazz Pharmaceuticals Inc.6$102
Kowa Pharmaceuticals America, Inc.7$95
Astellas Pharma US Inc6$93
Exact Sciences5$89
Axogen2$63
Supernus Pharmaceuticals, Inc.3$59
Eisai Inc.4$58
SK Life Science, Inc.2$58
Antares Pharma, Inc.3$54
Dexcom, Inc.3$51
Axsome Therapeutics, Inc.2$50
Boston Scientific2$47
Almatica Pharma LLC2$40
Orexo US, Inc.4$39
Paratek Pharmaceuticals, Inc.2$35
Upsher-smith Laboratories LLC2$35
Evoke Pharma, Inc.2$32
Neurocrine Biosciences, Inc.1$32
Nestle Healthcare Nutrition Inc.2$31
Intra-sana Laboratories1$29
Abbott2$25
Radius Health, Inc.1$24

How this compares

$6,018,695 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama →

Medicare billing

Part B allowed, 2024
$72,539
Medicare patients
145
Services billed
3,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →